title: Effect of human, recombinant interleukin 2 on Punta Toro virus infections in C57BL/6 mice.
abstract: The effect of human recombinant interleukin-2 (rIL-2) on Punta Toro virus (PTV) infection was investigated in C57BL/6 mice. Immunologic and viral parameters were assessed after mice were treated i.p. with rIL-2 for 5 days. Treatment of mice with 25000 and 12500 units/mouse of rIL-2 resulted in significant inhibition of the disease as indicated by increases in survival of mice as well as decreases in liver and serum virus titers. Serum glutamic oxalic acid and pyruvic acid transaminase levels were also lowered indicating reduced liver damage. Murine IL-2 production returned to normal or above-normal levels in rIL-2 treated mice. Natural killer cell activity was also moderately stimulated by rIL-2 treatment. Significant amounts of interferon were not detected in the sera of treated mice. Weight gain and survival rates were similar for both toxicity and normal controls indicating that rIL-2 treatments had no toxic effect.
authors.affiliation: Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan 84322-5600.
authors.forename: J R
authors.initials: JR
authors.lastname: Mead
authors.forename: R A
authors.initials: RA
authors.lastname: Burger
authors.forename: L J
authors.initials: LJ
authors.lastname: Yonk
authors.forename: J
authors.initials: J
authors.lastname: Coombs
authors.forename: R P
authors.initials: RP
authors.lastname: Warren
authors.forename: M
authors.initials: M
authors.lastname: Kende
authors.forename: J
authors.initials: J
authors.lastname: Huggins
authors.forename: R W
authors.initials: RW
authors.lastname: Sidwell
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D002043:Bunyaviridae / Q000187:drug effects* / Q000378:metabolism; D002044:Bunyaviridae Infections / Q000378:metabolism / Q000382:microbiology / Q000628:therapy*; D004334:Drug Administration Schedule; D006801:Humans; D007372:Interferons / Q000096:biosynthesis; D007376:Interleukin-2 / Q000096:biosynthesis / Q000627:therapeutic use*; D007694:Killer Cells, Natural / Q000276:immunology / Q000382:microbiology; D008099:Liver / Q000187:drug effects / Q000201:enzymology / Q000382:microbiology; D051379:Mice; D008810:Mice, Inbred C57BL; D011994:Recombinant Proteins / Q000627:therapeutic use*; D015430:Weight Gain / Q000187:drug effects
chemical_list: D000998:Antiviral Agents; D007376:Interleukin-2; D011994:Recombinant Proteins; D007372:Interferons